{"gene":"CDKL5","run_date":"2026-04-28T17:28:52","timeline":{"discoveries":[{"year":2005,"finding":"CDKL5 is a functional kinase capable of autophosphorylation and phosphorylation of MeCP2 in vitro; CDKL5 and MeCP2 interact both in vivo and in vitro, placing them in a common molecular pathway.","method":"In vitro kinase assay, co-immunoprecipitation (in vivo and in vitro binding)","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1 — in vitro kinase assay with direct substrate phosphorylation; replicated by multiple labs","pmids":["15917271"],"is_preprint":false},{"year":2006,"finding":"Disease-causing mutations in CDKL5 alter catalytic activity (both impaired and increased) and impair phosphorylation of its TEY activation-loop motif; the C-terminal domain negatively regulates catalytic activity and is required for proper sub-nuclear localization; CDKL5 can self-associate and mediates autophosphorylation of its own TEY motif.","method":"In vitro kinase assay, site-directed mutagenesis, subcellular fractionation/localization studies","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro kinase assays combined with mutagenesis of disease-causing mutations and localization experiments","pmids":["16935860"],"is_preprint":false},{"year":2005,"finding":"CDKL5 kinase activity is required for its function; disease-associated mutations cause loss of kinase autophosphorylation activity; the C-terminal domain regulates CDKL5 expression and autophosphorylation and determines perinuclear localization when removed; MeCP2 binds CDKL5 but is not a direct substrate.","method":"In vitro kinase assay (autophosphorylation), immunoprecipitation, subcellular localization studies","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1 — in vitro kinase assays with multiple mutants; replicated findings on C-terminal regulation","pmids":["16330482"],"is_preprint":false},{"year":2008,"finding":"CDKL5 shuttles between cytoplasm and nucleus; the C-terminal tail localizes the protein to the cytoplasm via active nuclear export; disease-causing C-terminal truncations result in constitutive nuclear localization, suggesting gain-of-function in the nuclear compartment.","method":"Immunostaining, Western blotting, subcellular fractionation, nuclear export inhibition experiments","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — direct localization experiments with functional consequence; replicated across multiple CDKL5 studies","pmids":["18701457"],"is_preprint":false},{"year":2013,"finding":"CDKL5 binds the scaffolding protein PSD-95 in a palmitoylation-dependent manner, and this interaction promotes targeting of CDKL5 to excitatory synapses; pathogenic C-terminal truncations diminish CDKL5-PSD-95 binding and synaptic accumulation; loss of CDKL5 or disruption of the CDKL5-PSD-95 interaction inhibits dendritic spine formation and growth.","method":"Co-immunoprecipitation, RNAi knockdown, live imaging, spine morphology analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — reciprocal co-IP with functional validation via RNAi and morphological readout","pmids":["23671101"],"is_preprint":false},{"year":2013,"finding":"Amphiphysin 1 (Amph1) is an endogenous cytoplasmic substrate of CDKL5; CDKL5 phosphorylates Amph1 at Ser-293; phosphorylation at this site reduces Amph1 affinity for endophilin, a protein involved in synaptic vesicle endocytosis; disease-causing missense mutations in the CDKL5 catalytic domain impair kinase activity toward Amph1.","method":"In vitro kinase assay, LC-MS/MS substrate identification, co-immunoprecipitation, mutagenesis","journal":"Archives of biochemistry and biophysics","confidence":"High","confidence_rationale":"Tier 1 — in vitro kinase assay with MS-identified phosphorylation site and functional consequence of phosphorylation","pmids":["23651931"],"is_preprint":false},{"year":2016,"finding":"HDAC4 is a direct phosphorylation target of CDKL5; CDKL5-dependent phosphorylation promotes HDAC4 cytoplasmic retention; in Cdkl5 KO mice, hypophosphorylated HDAC4 translocates to the nucleus, binds chromatin and MEF2A transcription factor, leading to reduced histone 3 acetylation and altered neuronal gene expression.","method":"In vitro kinase assay, immunofluorescence, Cdkl5 KO mouse model, HDAC4 inhibitor rescue","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1 — direct substrate phosphorylation shown in vitro and validated in vivo with functional rescue","pmids":["27466189"],"is_preprint":false},{"year":2012,"finding":"Loss of CDKL5 in mice disrupts multiple signal transduction pathways including the AKT-mTOR cascade, as revealed by kinome profiling; Cdkl5 KO mice show autistic-like social deficits, motor impairment, and fear memory impairment.","method":"Cdkl5 KO mouse model, kinome profiling, behavioral assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — KO mouse with defined behavioral phenotype + kinome profiling establishing pathway disruption","pmids":["23236174"],"is_preprint":false},{"year":2014,"finding":"Loss of CDKL5 impairs hippocampal neurogenesis: increases proliferation of neural precursors, increases apoptosis of postmitotic granule neuron precursors, reduces total granule cell number, and causes severe dendritic hypotrophy; these defects are associated with impaired AKT/GSK-3β signaling.","method":"Cdkl5 KO mouse model, immunostaining, Western blotting, hippocampus-dependent memory assays","journal":"Neurobiology of disease","confidence":"High","confidence_rationale":"Tier 2 — KO mouse with multiple cellular phenotypes linked to specific signaling pathway","pmids":["24952363"],"is_preprint":false},{"year":2018,"finding":"Using chemical genetics, CDKL5 was found to phosphorylate three microtubule-associated proteins: MAP1S, EB2, and ARHGEF2 at defined sites; substrate phosphorylations are reduced in CDKL5 KO mouse neurons; CDKL5 regulates dendritic microtubule dynamics via phosphorylation of MAP1S, which promotes MAP1S dissociation from microtubules; anterograde cargo trafficking is compromised in CDKL5 KO dendrites.","method":"Chemical genetics (analog-sensitive kinase), phosphoproteomics, shRNA rescue, live imaging of EB3-GFP microtubule dynamics in KO neurons","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 — chemical genetic substrate identification with in vivo validation and functional microtubule dynamics assay","pmids":["30266824"],"is_preprint":false},{"year":2018,"finding":"Quantitative phosphoproteomic screening identified MAP1S (pSer900), CEP131 (pSer35), and DLG5 as cellular CDKL5 substrates; the consensus phosphorylation motif for CDKL5 is RPXSA; pathogenic CDKL5 mutations cause major reduction in CDKL5 activity both in vitro and in cells.","method":"Quantitative phosphoproteomics, phospho-specific antibodies, in vitro kinase assays with disease mutants","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 — phosphoproteomic screen validated with phospho-specific antibodies and in vitro kinase assays","pmids":["30266825"],"is_preprint":false},{"year":2017,"finding":"CDKL5 controls postsynaptic localization of GluN2B-containing NMDA receptors and SAP102 in hippocampal CA1; Cdkl5 KO mice show increased NMDA/AMPA ratio and prolonged NMDA-EPSC decay; GluN2B and SAP102 are overaccumulated in the postsynaptic density of Cdkl5 KO mice; GluN2B-selective antagonist ifenprodil abrogates NMDA-induced hyperexcitability.","method":"Cdkl5 KO mouse, electrophysiology (patch-clamp), subcellular fractionation, immunoelectron microscopy","journal":"Neurobiology of disease","confidence":"High","confidence_rationale":"Tier 2 — KO mouse with electrophysiology, fractionation, and immunoEM; multiple orthogonal methods","pmids":["28688852"],"is_preprint":false},{"year":2017,"finding":"Loss of CDKL5 specifically in forebrain glutamatergic neurons impairs hippocampal-dependent memory; CDKL5-deficient pyramidal neurons show decreased dendritic complexity, increased mEPSC and mIPSC frequency, and hyperexcitability in dendritic domains constrained by elevated inhibition.","method":"Conditional KO mouse (glutamatergic neuron-specific), behavioral assays, patch-clamp electrophysiology, voltage-sensitive dye imaging","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 — cell-type specific KO with defined behavioral and circuit phenotypes using multiple methods","pmids":["28674172"],"is_preprint":false},{"year":2016,"finding":"CDKL5 interacts with shootin1, a brain-specific determinant of axon formation; CDKL5 and shootin1 co-localize at the distal tip of outgrowing axons; CDKL5 overexpression causes supernumerary axons while silencing disrupts neuronal polarization; shootin1 phosphorylation is reduced in CDKL5-silenced neurons; the two proteins act in a common pathway for axon specification.","method":"Yeast two-hybrid, co-immunoprecipitation, live imaging, RNAi silencing, overexpression in primary hippocampal neurons","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — co-IP validated interaction with functional neuronal polarization phenotype; single lab","pmids":["26849555"],"is_preprint":false},{"year":2017,"finding":"CDKL5 interacts with IQGAP1; loss of CDKL5 impairs cell migration and IQGAP1 localization at the leading edge; CDKL5 is required for IQGAP1 to form a functional complex with Rac1 and CLIP170 (microtubule plus-end tracking protein), thereby regulating microtubule dynamics.","method":"Co-immunoprecipitation, cell migration assay, immunofluorescence localization, rescue with pregnenolone","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 — co-IP with functional migration and microtubule dynamics readout; single lab","pmids":["28641386"],"is_preprint":false},{"year":2015,"finding":"Neuronal depolarization induces rapid increase in CDKL5 levels via extrasomatic synthesis; in mature neurons, NMDA receptor stimulation induces protein phosphatase 1-dependent dephosphorylation of CDKL5 that is required for its proteasome-dependent degradation, providing activity-dependent control of CDKL5 levels.","method":"Primary neuron cultures, pharmacological inhibitors, metabolic labeling, proteasome inhibition","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — multiple pharmacological approaches in primary neurons; single lab","pmids":["25555910"],"is_preprint":false},{"year":2016,"finding":"DYRK1A binds to and phosphorylates CDKL5 at Ser-308 (near the nuclear localization signal); phosphorylation at Ser-308 promotes cytosolic localization of CDKL5; the phosphomimetic S308D mutation shifts CDKL5 to cytoplasm while S308A remains nuclear.","method":"Co-immunoprecipitation, site-directed mutagenesis, subcellular localization experiments in Neuro2a cells","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — co-IP with mutagenesis and localization readout; single lab","pmids":["27840050"],"is_preprint":false},{"year":2010,"finding":"CDKL5 (Cdkl5) is a MeCP2-repressed target gene; increased MeCP2 levels repress Cdkl5 expression in rat brain; Cdkl5 is regulated by DNA methylation, as DNMT inhibitors or MeCP2 knockdown induce its expression; cocaine increases Cdkl5 gene methylation and MeCP2 binding to the Cdkl5 locus in striatum.","method":"siRNA knockdown, MeCP2 overexpression, DNMT inhibitor treatment, ChIP, in vivo cocaine model","journal":"Neurobiology of disease","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal approaches showing MeCP2-dependent transcriptional regulation; single lab","pmids":["20211261"],"is_preprint":false},{"year":2019,"finding":"Selective loss of CDKL5 in GABAergic neurons leads to autistic-like phenotypes accompanied by excessive glutamatergic transmission and increased postsynaptic NMDA receptor levels; acute low-dose NMDAR inhibition ameliorates autistic-like behaviors in GABAergic CDKL5 KO mice and in a CDD-associated R59X knockin mouse.","method":"GABAergic-neuron-specific conditional KO mouse, R59X knockin mouse, behavioral assays, electrophysiology, receptor level measurements","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — cell-type specific KO with behavioral, electrophysiological and molecular phenotyping; replicated in two mouse models","pmids":["31201320"],"is_preprint":false},{"year":2021,"finding":"CDKL5 is recruited to sites of DNA damage in actively transcribed nuclear regions; a phosphoproteomic screen identified Elongin A (ELOA) as a nuclear CDKL5 substrate phosphorylated at a CDKL5 consensus motif; recruitment of CDKL5 and ELOA requires active transcription and poly(ADP-ribose) (PAR) synthesis; CDKL5 can bind PAR; CDKL5 kinase activity is essential for transcriptional silencing induced by DNA double-strand breaks.","method":"Live-cell imaging of DNA damage recruitment, quantitative phosphoproteomics, PAR binding assay, kinase-inactive mutant analysis","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 — phosphoproteomic substrate identification with functional validation using kinase-inactive mutants and direct PAR binding","pmids":["34605059"],"is_preprint":false},{"year":2019,"finding":"SMAD3 is a direct phosphorylation target of CDKL5; CDKL5-dependent phosphorylation promotes SMAD3 protein stability; restoration of SMAD3 signaling via TGF-β1 normalizes defective neuronal survival and maturation in Cdkl5 KO neurons and prevents NMDA-induced hippocampal cell death in vivo.","method":"In vitro kinase assay, Cdkl5 KO mouse model, TGF-β1 in vivo treatment, immunostaining","journal":"Brain pathology","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro kinase assay plus KO mouse rescue experiment; single lab","pmids":["30793413"],"is_preprint":false},{"year":2020,"finding":"CDKL5 phosphorylates SOX9, suppressing its pro-survival transcriptional activity in renal tubular epithelial cells; Cdkl5 genetic or pharmacological inhibition mitigates nephrotoxic and ischemia-associated acute kidney injury in mouse models.","method":"Kinome RNAi screen, kinase assay (activation-specific antibodies), RTEC-specific Cdkl5 KO mouse, small molecule inhibitor (AST-487)","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — kinase assay validation, cell-type specific KO, and pharmacological rescue; multiple orthogonal approaches","pmids":["32317630"],"is_preprint":false},{"year":2012,"finding":"CDKL5 overexpression arrests the cell cycle at G0/G1 and induces cellular differentiation in neuroblastoma cells; CDKL5 expression is directly repressed by MYCN transcription factor, which binds the CDKL5 promoter.","method":"Cell cycle analysis (flow cytometry), differentiation assays, ChIP, promoter reporter assays, MYCN overexpression/knockdown","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 — multiple complementary approaches in a single study; functional cell cycle phenotype with defined transcriptional mechanism","pmids":["22921766"],"is_preprint":false},{"year":2023,"finding":"CDKL5 phosphorylates the voltage-gated Ca2+ channel Cav2.3 (encoded by CACNA1E) as a physiological substrate in mice and humans; loss of Cav2.3 phosphorylation leads to channel gain-of-function via slower inactivation and enhanced cholinergic stimulation, resulting in increased neuronal excitability; Cav2.3 phosphomutant mice recapitulate aspects of CDD.","method":"SILAC-based phosphoproteomic screen, recombinant channel electrophysiology, Cav2.3 phosphomutant mouse model, interdisciplinary phenotyping","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 — phosphoproteomic substrate identification combined with reconstituted channel electrophysiology and in vivo knockin mouse","pmids":["38081835"],"is_preprint":false},{"year":2023,"finding":"CDKL5 kinase activity is required for efficient synaptic vesicle (SV) endocytosis in central nerve terminals; kinase-inactive CDKL5 mutations fail to restore SV endocytosis in Cdkl5 KO rat neurons; the isolated CDKL5 kinase domain is sufficient to rescue SV endocytosis; amphiphysin 1 phosphorylation is not required for this presynaptic role.","method":"Cdkl5 KO rat primary hippocampal neurons, genetically encoded SV reporter, kinase-inactive mutant rescue, isolated kinase domain rescue","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 1 — in vitro kinase requirement established with kinase-inactive mutants and domain rescue in KO neurons","pmids":["36759195"],"is_preprint":false},{"year":2015,"finding":"CDKL5 substrate recognition requires an arginyl residue at the P-3 position and a prolyl residue at P-2 relative to the phospho-acceptor serine; the consensus motif is RPXSX; the CLAP domain structure of amphiphysin 1 is also required for efficient phosphorylation.","method":"In vitro kinase assay with point-mutant and deletion-mutant substrates (Amph1 and Amph2)","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — systematic in vitro mutagenesis defining substrate consensus motif","pmids":["25905439"],"is_preprint":false},{"year":2021,"finding":"Postdevelopmental loss of CDKL5 disrupts hippocampal circuit communication, dendritic spine morphology, and multiple behavioral domains; restoration of Cdkl5 expression after early development ameliorates CDD-related behavioral impairments and aberrant NMDA receptor signaling, demonstrating reversibility of CDKL5 deficiency phenotypes.","method":"Conditional temporal Cdkl5 KO and rescue mouse models, behavioral assays, electrophysiology, spine morphology analysis","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — temporal conditional KO and rescue in mice with behavioral and electrophysiological readouts; multiple orthogonal methods","pmids":["34651584"],"is_preprint":false},{"year":2024,"finding":"CDKL5 and EB2 phospho-Ser222 (a CDKL5 substrate) are expressed in excitatory and inhibitory neurons but not astrocytes; approximately 15-20% of EB2 pS222 remains in Cdkl5 KO brains, attributable to a compensating kinase activity; CDKL2 and ICK can phosphorylate EB2 S222; dual Cdkl5/Cdkl2 KO mice demonstrate that CDKL2 phosphorylates CDKL5 substrates in vivo.","method":"Conditional Cdkl5 KO mice (excitatory, inhibitory, astrocyte-specific), phospho-specific antibody for EB2 pS222, kinase screen in HEK293T cells, dual KO mouse","journal":"Molecular psychiatry","confidence":"High","confidence_rationale":"Tier 2 — cell-type specific KO combined with in vivo phospho-antibody readout and genetic validation via dual KO","pmids":["38326557"],"is_preprint":false}],"current_model":"CDKL5 is a brain-enriched serine/threonine kinase that phosphorylates multiple substrates—including MeCP2, HDAC4, SMAD3, MAP1S, EB2, ARHGEF2, CEP131, DLG5, amphiphysin 1, Cav2.3, and Elongin A—using a consensus RPX(S/T) motif; its catalytic activity is regulated by autophosphorylation of a TEY activation loop, phosphorylation by DYRK1A at Ser-308 (controlling nuclear/cytoplasmic distribution), activity-dependent dephosphorylation by PP1 and proteasomal degradation; through these substrates CDKL5 controls dendritic microtubule dynamics, synaptic vesicle endocytosis, postsynaptic NMDA and AMPA receptor localization, dendritic spine morphogenesis, neuronal polarization, transcription-coupled DNA damage responses, and neuronal survival, with loss of CDKL5 function disrupting AKT/GSK-3β, mTOR, and HDAC4/MEF2A signaling pathways to cause the epileptic encephalopathy and neurodevelopmental deficits characteristic of CDKL5 deficiency disorder."},"narrative":{"teleology":[{"year":2005,"claim":"Establishing that CDKL5 is a functional kinase that autophosphorylates and interacts with MeCP2 placed CDKL5 into an active signaling pathway rather than being merely a disease-associated gene of unknown function.","evidence":"In vitro kinase assay and co-immunoprecipitation in mammalian cells","pmids":["15917271","16330482"],"confidence":"High","gaps":["Whether MeCP2 is a direct physiological substrate remained disputed between the two 2005 studies","Endogenous substrates in neurons were unknown","Upstream regulators of CDKL5 kinase activity were undefined"]},{"year":2006,"claim":"Demonstrating that disease-causing mutations alter TEY activation-loop phosphorylation and that the C-terminal domain negatively regulates catalytic activity and nuclear localization established the first structure–function framework for CDKL5.","evidence":"Site-directed mutagenesis of patient mutations with in vitro kinase assays and subcellular fractionation","pmids":["16935860"],"confidence":"High","gaps":["Crystal structure of the kinase domain was unavailable","The mechanism by which the C-terminal tail inhibits catalysis was undefined","Whether TEY phosphorylation is purely autophosphorylation or also mediated by upstream kinases was unresolved"]},{"year":2008,"claim":"Showing that CDKL5 actively shuttles between nucleus and cytoplasm, with disease-causing C-terminal truncations causing constitutive nuclear accumulation, revealed that mislocalization is a pathogenic mechanism.","evidence":"Immunostaining, subcellular fractionation, and nuclear export inhibition in cell lines","pmids":["18701457"],"confidence":"High","gaps":["The nuclear export signal sequence was not precisely mapped","Functional consequences of nuclear-restricted CDKL5 in neurons were untested"]},{"year":2012,"claim":"Cdkl5 knockout mice displaying autistic-like behaviors and disrupted AKT-mTOR signaling established the first in vivo disease model and identified downstream pathway perturbations, while parallel work showed CDKL5 can arrest cell cycle and is transcriptionally repressed by MYCN.","evidence":"Cdkl5 KO mouse behavioral and kinome profiling; cell cycle analysis and ChIP in neuroblastoma cells","pmids":["23236174","22921766"],"confidence":"High","gaps":["Whether AKT-mTOR disruption is a direct or indirect consequence of CDKL5 loss was unknown","Cell-type contributions to behavioral phenotypes were unresolved"]},{"year":2013,"claim":"Identification of amphiphysin 1 as a direct substrate (pSer-293) linking CDKL5 to synaptic vesicle endocytosis, and of the PSD-95 interaction linking CDKL5 to excitatory synapse targeting and dendritic spine formation, provided the first mechanistic connections between CDKL5 kinase activity and synaptic biology.","evidence":"LC-MS/MS substrate mapping, co-IP of CDKL5–PSD-95, RNAi-mediated loss-of-function with spine morphology readout","pmids":["23651931","23671101"],"confidence":"High","gaps":["Whether amphiphysin 1 phosphorylation fully explains presynaptic defects was untested","The palmitoylation site on CDKL5 required for PSD-95 binding was not identified"]},{"year":2015,"claim":"Systematic mutagenesis defined the CDKL5 substrate consensus motif as RPX(S/T), and activity-dependent regulation of CDKL5 protein levels via PP1 dephosphorylation and proteasomal degradation was discovered, linking synaptic activity to kinase abundance.","evidence":"In vitro kinase assays with point-mutant substrates; pharmacological dissection of CDKL5 turnover in primary neurons","pmids":["25905439","25555910"],"confidence":"High","gaps":["The specific phosphosites on CDKL5 targeted by PP1 for degradation were not mapped","In vivo relevance of activity-dependent CDKL5 degradation was not tested"]},{"year":2016,"claim":"Identification of HDAC4 and shootin1 as CDKL5 targets/interactors expanded the functional repertoire to include epigenetic regulation (HDAC4 cytoplasmic retention controlling MEF2A-dependent transcription) and neuronal polarization (axon specification via shootin1), while DYRK1A-mediated Ser-308 phosphorylation was found to control CDKL5 nuclear–cytoplasmic distribution.","evidence":"In vitro kinase assays, Cdkl5 KO mouse with HDAC4 inhibitor rescue, yeast two-hybrid and co-IP for shootin1, mutagenesis of Ser-308","pmids":["27466189","26849555","27840050"],"confidence":"High","gaps":["The specific HDAC4 phosphosite(s) were not fully mapped","Shootin1 interaction was from a single lab and awaits independent confirmation","Whether DYRK1A regulation of CDKL5 localization occurs in vivo in neurons was untested"]},{"year":2017,"claim":"Cell-type-specific knockout studies demonstrated that CDKL5 loss in forebrain glutamatergic neurons causes hippocampal memory deficits, dendritic hypotrophy, and altered excitability, while molecular analysis revealed overaccumulation of GluN2B-NMDA receptors at postsynaptic densities as a key pathogenic mechanism.","evidence":"Glutamatergic-neuron conditional KO mice, electrophysiology, immunoelectron microscopy, GluN2B-selective antagonist rescue","pmids":["28674172","28688852"],"confidence":"High","gaps":["Whether CDKL5 directly phosphorylates NMDA receptor subunits or acts indirectly was unknown","Contribution of GABAergic neuron CDKL5 loss was untested at this point"]},{"year":2018,"claim":"Chemical-genetic and quantitative phosphoproteomic screens converged on MAP1S, EB2, ARHGEF2, CEP131, and DLG5 as bona fide CDKL5 substrates, establishing that CDKL5 controls dendritic microtubule dynamics through MAP1S phosphorylation-dependent dissociation from microtubules.","evidence":"Analog-sensitive kinase allele, SILAC phosphoproteomics, phospho-specific antibodies, live EB3-GFP imaging in KO neurons","pmids":["30266824","30266825"],"confidence":"High","gaps":["Functional roles of CEP131 and DLG5 phosphorylation were not characterized","Whether microtubule dynamics defects underlie spine morphology changes was not directly tested"]},{"year":2019,"claim":"GABAergic-neuron-specific CDKL5 loss was shown to cause autistic-like behaviors with excessive NMDA signaling, rescuable by low-dose NMDAR antagonism, while SMAD3 was identified as a CDKL5 substrate whose phosphorylation promotes neuronal survival via TGF-β signaling.","evidence":"GABAergic conditional KO and R59X knockin mice with NMDAR antagonist rescue; in vitro kinase assay for SMAD3 with TGF-β1 in vivo rescue in KO","pmids":["31201320","30793413"],"confidence":"High","gaps":["The presynaptic versus postsynaptic locus of NMDAR dysregulation in GABAergic KO was unclear","SMAD3 as a substrate was from a single lab and the specific phosphosite was not fully characterized"]},{"year":2021,"claim":"CDKL5 was found to be recruited to transcription-coupled DNA damage sites via PAR binding, where it phosphorylates Elongin A to silence transcription at breaks, revealing an unexpected nuclear function beyond synaptic signaling; separately, temporal rescue experiments demonstrated that CDD phenotypes are reversible upon postnatal CDKL5 restoration.","evidence":"Live-cell DNA damage imaging, phosphoproteomics identifying Elongin A, PAR-binding assay; conditional temporal KO/rescue mice with behavioral and electrophysiological readouts","pmids":["34605059","34651584"],"confidence":"High","gaps":["Whether transcription-coupled DNA damage repair contributes to CDD neuropathology is unknown","The degree of phenotypic rescue achievable in adult animals was not fully explored"]},{"year":2023,"claim":"Cav2.3 was identified as a physiological CDKL5 substrate whose phosphorylation accelerates channel inactivation; loss of this phosphorylation causes channel gain-of-function and neuronal hyperexcitability, directly connecting CDKL5 loss to ion channel dysfunction, while CDKL5 kinase activity was separately shown to be required for efficient synaptic vesicle endocytosis independent of amphiphysin 1 phosphorylation.","evidence":"SILAC phosphoproteomics, recombinant channel electrophysiology, Cav2.3 phosphomutant knockin mouse; Cdkl5 KO rat neurons with SV reporter and kinase-dead rescue","pmids":["38081835","36759195"],"confidence":"High","gaps":["The specific CDKL5 substrate mediating synaptic vesicle endocytosis (if not amphiphysin 1) is unknown","Whether Cav2.3 phosphorylation loss accounts for seizure susceptibility in CDD patients is untested"]},{"year":2024,"claim":"Dual knockout experiments revealed that CDKL2 provides compensatory phosphorylation of CDKL5 substrates (notably EB2 at Ser-222) in vivo, establishing kinase redundancy that must be considered when interpreting single-KO phenotypes.","evidence":"Cell-type specific Cdkl5 KO with phospho-EB2 antibody; HEK293T kinase screen; Cdkl5/Cdkl2 dual KO mouse","pmids":["38326557"],"confidence":"High","gaps":["The full set of substrates shared between CDKL5 and CDKL2 is undefined","Whether CDKL2 compensation is neuroprotective or masks disease severity in CDD is unknown"]},{"year":null,"claim":"Key unresolved questions include the structural basis of CDKL5 substrate recognition, the identity of the presynaptic substrate(s) required for synaptic vesicle endocytosis, whether transcription-coupled DNA damage repair contributes to CDD neuropathology, and the extent to which CDKL2/ICK compensation modulates disease severity.","evidence":"","pmids":[],"confidence":"High","gaps":["No crystal or cryo-EM structure of full-length CDKL5 with substrate or regulatory domains","Presynaptic CDKL5 substrate for SV endocytosis remains unidentified","Contribution of nuclear DNA damage response function to neurological phenotypes is untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,5,6,9,10,19,20,21,23,25]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,5,6,10,23,25]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,3,19]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[3,5,16]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[4]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[7,8,20]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[4,9,11,12,18,23,24]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[19]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[8,13]}],"complexes":[],"partners":["MECP2","DLG4","AMPH","HDAC4","MAP1S","MAPRE2","DYRK1A","IQGAP1"],"other_free_text":[]},"mechanistic_narrative":"CDKL5 is a brain-enriched serine/threonine kinase that controls dendritic morphogenesis, synaptic function, neuronal excitability, and survival by phosphorylating diverse substrates at a consensus RPX(S/T) motif. Its catalytic activity, regulated by autophosphorylation of a TEY activation-loop motif and by DYRK1A-mediated phosphorylation at Ser-308 controlling nuclear–cytoplasmic shuttling, targets microtubule regulators (MAP1S, EB2, ARHGEF2), synaptic proteins (amphiphysin 1, PSD-95-associated complexes, Cav2.3), transcriptional regulators (HDAC4, SMAD3, Elongin A), and centrosomal/polarity factors (CEP131, DLG5), thereby governing dendritic microtubule dynamics, synaptic vesicle endocytosis, NMDA receptor localization, and transcription-coupled DNA damage responses [PMID:30266824, PMID:30266825, PMID:23651931, PMID:27466189, PMID:34605059, PMID:38081835, PMID:36759195]. Loss-of-function mutations cause CDKL5 deficiency disorder, an epileptic encephalopathy with neurodevelopmental deficits characterized by disrupted AKT/GSK-3β and mTOR signaling, NMDA receptor overaccumulation, and dendritic hypotrophy, phenotypes that are reversible upon postnatal gene restoration in mice [PMID:23236174, PMID:24952363, PMID:28688852, PMID:34651584]. CDKL2 and ICK provide partially compensatory kinase activity toward CDKL5 substrates such as EB2 in vivo [PMID:38326557]."},"prefetch_data":{"uniprot":{"accession":"O76039","full_name":"Cyclin-dependent kinase-like 5","aliases":["Serine/threonine-protein kinase 9"],"length_aa":960,"mass_kda":107.5,"function":"Mediates phosphorylation of MECP2 (PubMed:15917271, PubMed:16935860). May regulate ciliogenesis (PubMed:29420175)","subcellular_location":"Nucleus; Cytoplasm, cytoskeleton, cilium basal body; Cytoplasm, cytoskeleton, microtubule organizing center, centrosome","url":"https://www.uniprot.org/uniprotkb/O76039/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CDKL5","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CDKL5","total_profiled":1310},"omim":[{"mim_id":"613443","title":"NEURODEVELOPMENTAL DISORDER WITH HYPOTONIA, STEREOTYPIC HAND MOVEMENTS, AND IMPAIRED LANGUAGE; NEDHSIL","url":"https://www.omim.org/entry/613443"},{"mim_id":"608818","title":"NETRIN G1; NTNG1","url":"https://www.omim.org/entry/608818"},{"mim_id":"608459","title":"CYCLIN-DEPENDENT KINASE-LIKE 3; CDKL3","url":"https://www.omim.org/entry/608459"},{"mim_id":"603442","title":"CYCLIN-DEPENDENT KINASE-LIKE 2; CDKL2","url":"https://www.omim.org/entry/603442"},{"mim_id":"603441","title":"CYCLIN-DEPENDENT KINASE-LIKE 1; CDKL1","url":"https://www.omim.org/entry/603441"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"brain","ntpm":12.8}],"url":"https://www.proteinatlas.org/search/CDKL5"},"hgnc":{"alias_symbol":["EIEE2","CFAP247"],"prev_symbol":["STK9"]},"alphafold":{"accession":"O76039","domains":[{"cath_id":"3.30.200.20","chopping":"2-92","consensus_level":"medium","plddt":82.8441,"start":2,"end":92},{"cath_id":"1.10.510.10","chopping":"94-303","consensus_level":"high","plddt":92.4732,"start":94,"end":303}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O76039","model_url":"https://alphafold.ebi.ac.uk/files/AF-O76039-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O76039-F1-predicted_aligned_error_v6.png","plddt_mean":53.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CDKL5","jax_strain_url":"https://www.jax.org/strain/search?query=CDKL5"},"sequence":{"accession":"O76039","fasta_url":"https://rest.uniprot.org/uniprotkb/O76039.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O76039/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O76039"}},"corpus_meta":[{"pmid":"15492925","id":"PMC_15492925","title":"Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation.","date":"2004","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15492925","citation_count":382,"is_preprint":false},{"pmid":"15917271","id":"PMC_15917271","title":"CDKL5 belongs to the same molecular pathway of MeCP2 and it is responsible for the early-onset seizure variant of Rett syndrome.","date":"2005","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15917271","citation_count":254,"is_preprint":false},{"pmid":"18790821","id":"PMC_18790821","title":"Key clinical features to identify girls with CDKL5 mutations.","date":"2008","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/18790821","citation_count":224,"is_preprint":false},{"pmid":"15689447","id":"PMC_15689447","title":"CDKL5/STK9 is mutated in Rett syndrome variant with infantile spasms.","date":"2005","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15689447","citation_count":185,"is_preprint":false},{"pmid":"23236174","id":"PMC_23236174","title":"Loss of CDKL5 disrupts kinome profile and event-related potentials leading to autistic-like phenotypes in mice.","date":"2012","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/23236174","citation_count":176,"is_preprint":false},{"pmid":"18701457","id":"PMC_18701457","title":"CDKL5 expression is modulated during neuronal development and its subcellular distribution is tightly regulated by the C-terminal tail.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18701457","citation_count":170,"is_preprint":false},{"pmid":"24838000","id":"PMC_24838000","title":"Mapping pathological phenotypes in a mouse model of CDKL5 disorder.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24838000","citation_count":153,"is_preprint":false},{"pmid":"18266744","id":"PMC_18266744","title":"The three stages of epilepsy in patients with CDKL5 mutations.","date":"2008","source":"Epilepsia","url":"https://pubmed.ncbi.nlm.nih.gov/18266744","citation_count":150,"is_preprint":false},{"pmid":"16015284","id":"PMC_16015284","title":"Early onset seizures and Rett-like features associated with mutations in CDKL5.","date":"2005","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/16015284","citation_count":134,"is_preprint":false},{"pmid":"16935860","id":"PMC_16935860","title":"Functional consequences of mutations in CDKL5, an X-linked gene involved in infantile spasms and mental retardation.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16935860","citation_count":131,"is_preprint":false},{"pmid":"31313283","id":"PMC_31313283","title":"CDKL5 deficiency disorder: Relationship between genotype, epilepsy, cortical visual impairment, and development.","date":"2019","source":"Epilepsia","url":"https://pubmed.ncbi.nlm.nih.gov/31313283","citation_count":125,"is_preprint":false},{"pmid":"24952363","id":"PMC_24952363","title":"Loss of CDKL5 impairs survival and dendritic growth of newborn neurons by altering AKT/GSK-3β signaling.","date":"2014","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/24952363","citation_count":111,"is_preprint":false},{"pmid":"27080038","id":"PMC_27080038","title":"Prevalence and onset of comorbidities in the CDKL5 disorder differ from Rett syndrome.","date":"2016","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/27080038","citation_count":109,"is_preprint":false},{"pmid":"16330482","id":"PMC_16330482","title":"CDKL5/Stk9 kinase inactivation is associated with neuronal developmental disorders.","date":"2005","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16330482","citation_count":102,"is_preprint":false},{"pmid":"28688852","id":"PMC_28688852","title":"CDKL5 controls postsynaptic localization of GluN2B-containing NMDA receptors in the hippocampus and regulates seizure susceptibility.","date":"2017","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/28688852","citation_count":101,"is_preprint":false},{"pmid":"23671101","id":"PMC_23671101","title":"Palmitoylation-dependent CDKL5-PSD-95 interaction regulates synaptic targeting of CDKL5 and dendritic spine development.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/23671101","citation_count":95,"is_preprint":false},{"pmid":"22779007","id":"PMC_22779007","title":"What we know and would like to know about CDKL5 and its involvement in epileptic encephalopathy.","date":"2012","source":"Neural plasticity","url":"https://pubmed.ncbi.nlm.nih.gov/22779007","citation_count":86,"is_preprint":false},{"pmid":"27770071","id":"PMC_27770071","title":"Seizure variables and their relationship to genotype and functional abilities in the CDKL5 disorder.","date":"2016","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/27770071","citation_count":85,"is_preprint":false},{"pmid":"19793311","id":"PMC_19793311","title":"Mutational spectrum of CDKL5 in early-onset encephalopathies: a study of a large collection of French patients and review of the literature.","date":"2009","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19793311","citation_count":84,"is_preprint":false},{"pmid":"20211261","id":"PMC_20211261","title":"CDKL5 is a brain MeCP2 target gene regulated by DNA methylation.","date":"2010","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/20211261","citation_count":83,"is_preprint":false},{"pmid":"25657822","id":"PMC_25657822","title":"There is variability in the attainment of developmental milestones in the CDKL5 disorder.","date":"2015","source":"Journal of neurodevelopmental disorders","url":"https://pubmed.ncbi.nlm.nih.gov/25657822","citation_count":82,"is_preprint":false},{"pmid":"27466189","id":"PMC_27466189","title":"HDAC4: a key factor underlying brain developmental alterations in CDKL5 disorder.","date":"2016","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27466189","citation_count":81,"is_preprint":false},{"pmid":"27528505","id":"PMC_27528505","title":"Functional abilities in children and adults with the CDKL5 disorder.","date":"2016","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/27528505","citation_count":79,"is_preprint":false},{"pmid":"30246934","id":"PMC_30246934","title":"Molecular and Synaptic Bases of CDKL5 Disorder.","date":"2018","source":"Developmental neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/30246934","citation_count":77,"is_preprint":false},{"pmid":"28674172","id":"PMC_28674172","title":"Loss of CDKL5 in Glutamatergic Neurons Disrupts Hippocampal Microcircuitry and Leads to Memory Impairment in Mice.","date":"2017","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/28674172","citation_count":77,"is_preprint":false},{"pmid":"21750574","id":"PMC_21750574","title":"iPS cells to model CDKL5-related disorders.","date":"2011","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/21750574","citation_count":73,"is_preprint":false},{"pmid":"30266824","id":"PMC_30266824","title":"Chemical genetic identification of CDKL5 substrates reveals its role in neuronal microtubule dynamics.","date":"2018","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/30266824","citation_count":72,"is_preprint":false},{"pmid":"23283985","id":"PMC_23283985","title":"CDKL5 regulates flagellar length and localizes to the base of the flagella in Chlamydomonas.","date":"2013","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/23283985","citation_count":69,"is_preprint":false},{"pmid":"30266825","id":"PMC_30266825","title":"Phosphoproteomic screening identifies physiological substrates of the CDKL5 kinase.","date":"2018","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/30266825","citation_count":65,"is_preprint":false},{"pmid":"31201320","id":"PMC_31201320","title":"Altered NMDAR signaling underlies autistic-like features in mouse models of CDKL5 deficiency disorder.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31201320","citation_count":60,"is_preprint":false},{"pmid":"24916645","id":"PMC_24916645","title":"GluD1 is a common altered player in neuronal differentiation from both MECP2-mutated and CDKL5-mutated iPS cells.","date":"2014","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/24916645","citation_count":60,"is_preprint":false},{"pmid":"27965538","id":"PMC_27965538","title":"Lack of Cdkl5 Disrupts the Organization of Excitatory and Inhibitory Synapses and Parvalbumin Interneurons in the Primary Visual Cortex.","date":"2016","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/27965538","citation_count":60,"is_preprint":false},{"pmid":"27315173","id":"PMC_27315173","title":"Characterisation of CDKL5 Transcript Isoforms in Human and Mouse.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27315173","citation_count":59,"is_preprint":false},{"pmid":"26236424","id":"PMC_26236424","title":"Cytokine Dysregulation in MECP2- and CDKL5-Related Rett Syndrome: Relationships with Aberrant Redox Homeostasis, Inflammation, and ω-3 PUFAs.","date":"2015","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/26236424","citation_count":59,"is_preprint":false},{"pmid":"26143616","id":"PMC_26143616","title":"Inhibition of GSK3β rescues hippocampal development and learning in a mouse model of CDKL5 disorder.","date":"2015","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/26143616","citation_count":59,"is_preprint":false},{"pmid":"31147226","id":"PMC_31147226","title":"Severity Assessment in CDKL5 Deficiency Disorder.","date":"2019","source":"Pediatric neurology","url":"https://pubmed.ncbi.nlm.nih.gov/31147226","citation_count":58,"is_preprint":false},{"pmid":"23651931","id":"PMC_23651931","title":"Identification of amphiphysin 1 as an endogenous substrate for CDKL5, a protein kinase associated with X-linked neurodevelopmental disorder.","date":"2013","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/23651931","citation_count":58,"is_preprint":false},{"pmid":"30952813","id":"PMC_30952813","title":"AMPA Receptor Dysregulation and Therapeutic Interventions in a Mouse Model of CDKL5 Deficiency Disorder.","date":"2019","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/30952813","citation_count":57,"is_preprint":false},{"pmid":"19241098","id":"PMC_19241098","title":"Novel mutations in the CDKL5 gene, predicted effects and associated phenotypes.","date":"2009","source":"Neurogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/19241098","citation_count":57,"is_preprint":false},{"pmid":"29474534","id":"PMC_29474534","title":"CDKL5 protein substitution therapy rescues neurological phenotypes of a mouse model of CDKL5 disorder.","date":"2018","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29474534","citation_count":55,"is_preprint":false},{"pmid":"32317630","id":"PMC_32317630","title":"A kinome-wide screen identifies a CDKL5-SOX9 regulatory axis in epithelial cell death and kidney injury.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32317630","citation_count":53,"is_preprint":false},{"pmid":"34651584","id":"PMC_34651584","title":"Temporal manipulation of Cdkl5 reveals essential postdevelopmental functions and reversible CDKL5 deficiency disorder-related deficits.","date":"2021","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/34651584","citation_count":52,"is_preprint":false},{"pmid":"22678952","id":"PMC_22678952","title":"Recurrent mutations in the CDKL5 gene: genotype-phenotype relationships.","date":"2012","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/22678952","citation_count":50,"is_preprint":false},{"pmid":"29977282","id":"PMC_29977282","title":"Heterozygous CDKL5 Knockout Female Mice Are a Valuable Animal Model for CDKL5 Disorder.","date":"2018","source":"Neural plasticity","url":"https://pubmed.ncbi.nlm.nih.gov/29977282","citation_count":46,"is_preprint":false},{"pmid":"21748340","id":"PMC_21748340","title":"A novel transcript of cyclin-dependent kinase-like 5 (CDKL5) has an alternative C-terminus and is the predominant transcript in brain.","date":"2011","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21748340","citation_count":44,"is_preprint":false},{"pmid":"25315662","id":"PMC_25315662","title":"Neurodevelopmental and neurobehavioral characteristics in males and females with CDKL5 duplications.","date":"2014","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/25315662","citation_count":41,"is_preprint":false},{"pmid":"26849555","id":"PMC_26849555","title":"CDKL5 and Shootin1 Interact and Concur in Regulating Neuronal Polarization.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26849555","citation_count":41,"is_preprint":false},{"pmid":"27062609","id":"PMC_27062609","title":"Rett-like phenotypes: expanding the genetic heterogeneity to the KCNA2 gene and first familial case of CDKL5-related disease.","date":"2016","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27062609","citation_count":41,"is_preprint":false},{"pmid":"33341033","id":"PMC_33341033","title":"Exploring quality of life in individuals with a severe developmental and epileptic encephalopathy, CDKL5 Deficiency Disorder.","date":"2020","source":"Epilepsy research","url":"https://pubmed.ncbi.nlm.nih.gov/33341033","citation_count":41,"is_preprint":false},{"pmid":"20493745","id":"PMC_20493745","title":"Epilepsy caused by CDKL5 mutations.","date":"2010","source":"European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society","url":"https://pubmed.ncbi.nlm.nih.gov/20493745","citation_count":40,"is_preprint":false},{"pmid":"22921766","id":"PMC_22921766","title":"CDKL5, a novel MYCN-repressed gene, blocks cell cycle and promotes differentiation of neuronal cells.","date":"2012","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/22921766","citation_count":40,"is_preprint":false},{"pmid":"17049193","id":"PMC_17049193","title":"Seizures and electroencephalographic findings in CDKL5 mutations: case report and review.","date":"2006","source":"Brain & development","url":"https://pubmed.ncbi.nlm.nih.gov/17049193","citation_count":38,"is_preprint":false},{"pmid":"35997111","id":"PMC_35997111","title":"CDKL5 deficiency disorder: molecular insights and mechanisms of pathogenicity to fast-track therapeutic development.","date":"2022","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/35997111","citation_count":37,"is_preprint":false},{"pmid":"24564546","id":"PMC_24564546","title":"Clinical features and gene mutational spectrum of CDKL5-related diseases in a cohort of Chinese patients.","date":"2014","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24564546","citation_count":37,"is_preprint":false},{"pmid":"31618813","id":"PMC_31618813","title":"Rett Syndrome and CDKL5 Deficiency Disorder: From Bench to Clinic.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31618813","citation_count":36,"is_preprint":false},{"pmid":"31925439","id":"PMC_31925439","title":"Artificial escape from XCI by DNA methylation editing of the CDKL5 gene.","date":"2020","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/31925439","citation_count":36,"is_preprint":false},{"pmid":"34238328","id":"PMC_34238328","title":"Inhibition of microglia overactivation restores neuronal survival in a mouse model of CDKL5 deficiency disorder.","date":"2021","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/34238328","citation_count":36,"is_preprint":false},{"pmid":"18063413","id":"PMC_18063413","title":"Clinical and electroencephalographic features in patients with CDKL5 mutations: two new Italian cases and review of the literature.","date":"2007","source":"Epilepsy & behavior : E&B","url":"https://pubmed.ncbi.nlm.nih.gov/18063413","citation_count":34,"is_preprint":false},{"pmid":"16326141","id":"PMC_16326141","title":"Myoclonic encephalopathy in the CDKL5 gene mutation.","date":"2005","source":"Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/16326141","citation_count":33,"is_preprint":false},{"pmid":"35633486","id":"PMC_35633486","title":"CDKL5 Deficiency Disorder-Related Epilepsy: A Review of Current and Emerging Treatment.","date":"2022","source":"CNS drugs","url":"https://pubmed.ncbi.nlm.nih.gov/35633486","citation_count":31,"is_preprint":false},{"pmid":"33047306","id":"PMC_33047306","title":"Exploring genotype-phenotype relationships in the CDKL5 deficiency disorder using an international dataset.","date":"2020","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33047306","citation_count":30,"is_preprint":false},{"pmid":"30326240","id":"PMC_30326240","title":"Rescue of prepulse inhibition deficit and brain mitochondrial dysfunction by pharmacological stimulation of the central serotonin receptor 7 in a mouse model of CDKL5 Deficiency Disorder.","date":"2018","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30326240","citation_count":30,"is_preprint":false},{"pmid":"25555910","id":"PMC_25555910","title":"Synaptic synthesis, dephosphorylation, and degradation: a novel paradigm for an activity-dependent neuronal control of CDKL5.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25555910","citation_count":30,"is_preprint":false},{"pmid":"32587608","id":"PMC_32587608","title":"Cyclin-Dependent Kinase-Like 5 (CDKL5): Possible Cellular Signalling Targets and Involvement in CDKL5 Deficiency Disorder.","date":"2020","source":"Neural plasticity","url":"https://pubmed.ncbi.nlm.nih.gov/32587608","citation_count":29,"is_preprint":false},{"pmid":"34605059","id":"PMC_34605059","title":"CDKL5 kinase controls transcription-coupled responses to DNA damage.","date":"2021","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/34605059","citation_count":28,"is_preprint":false},{"pmid":"33989939","id":"PMC_33989939","title":"CDKL5 deficiency disorder in males: Five new variants and review of the literature.","date":"2021","source":"European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society","url":"https://pubmed.ncbi.nlm.nih.gov/33989939","citation_count":28,"is_preprint":false},{"pmid":"30793413","id":"PMC_30793413","title":"CDKL5 deficiency predisposes neurons to cell death through the deregulation of SMAD3 signaling.","date":"2019","source":"Brain pathology (Zurich, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/30793413","citation_count":28,"is_preprint":false},{"pmid":"29618004","id":"PMC_29618004","title":"The antidepressant tianeptine reverts synaptic AMPA receptor defects caused by deficiency of CDKL5.","date":"2018","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29618004","citation_count":28,"is_preprint":false},{"pmid":"34094641","id":"PMC_34094641","title":"Age-Related Cognitive and Motor Decline in a Mouse Model of CDKL5 Deficiency Disorder is Associated with Increased Neuronal Senescence and Death.","date":"2021","source":"Aging and disease","url":"https://pubmed.ncbi.nlm.nih.gov/34094641","citation_count":28,"is_preprint":false},{"pmid":"28641386","id":"PMC_28641386","title":"The neurosteroid pregnenolone reverts microtubule derangement induced by the loss of a functional CDKL5-IQGAP1 complex.","date":"2017","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28641386","citation_count":28,"is_preprint":false},{"pmid":"31122804","id":"PMC_31122804","title":"Phenotypic manifestations between male and female children with CDKL5 mutations.","date":"2019","source":"Brain & development","url":"https://pubmed.ncbi.nlm.nih.gov/31122804","citation_count":27,"is_preprint":false},{"pmid":"34547934","id":"PMC_34547934","title":"Cerebral Visual Impairment in CDKL5 Deficiency Disorder Correlates With Developmental Achievement.","date":"2021","source":"Journal of child neurology","url":"https://pubmed.ncbi.nlm.nih.gov/34547934","citation_count":26,"is_preprint":false},{"pmid":"33538404","id":"PMC_33538404","title":"Ataluren for drug-resistant epilepsy in nonsense variant-mediated Dravet syndrome and CDKL5 deficiency disorder.","date":"2021","source":"Annals of clinical and translational neurology","url":"https://pubmed.ncbi.nlm.nih.gov/33538404","citation_count":26,"is_preprint":false},{"pmid":"35795799","id":"PMC_35795799","title":"International Consensus Recommendations for the Assessment and Management of Individuals With CDKL5 Deficiency Disorder.","date":"2022","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/35795799","citation_count":25,"is_preprint":false},{"pmid":"33436160","id":"PMC_33436160","title":"Clinical manifestations and epilepsy treatment in Japanese patients with pathogenic CDKL5 variants.","date":"2021","source":"Brain & development","url":"https://pubmed.ncbi.nlm.nih.gov/33436160","citation_count":24,"is_preprint":false},{"pmid":"31450582","id":"PMC_31450582","title":"Splicing Mutations Impairing CDKL5 Expression and Activity Can be Efficiently Rescued by U1snRNA-Based Therapy.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31450582","citation_count":23,"is_preprint":false},{"pmid":"32032735","id":"PMC_32032735","title":"The green tea polyphenol epigallocatechin-3-gallate (EGCG) restores CDKL5-dependent synaptic defects in vitro and in vivo.","date":"2020","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/32032735","citation_count":23,"is_preprint":false},{"pmid":"32002787","id":"PMC_32002787","title":"Increased DNA Damage and Apoptosis in CDKL5-Deficient Neurons.","date":"2020","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/32002787","citation_count":22,"is_preprint":false},{"pmid":"21765152","id":"PMC_21765152","title":"Clinical phenotype of 5 females with a CDKL5 mutation.","date":"2011","source":"Journal of child neurology","url":"https://pubmed.ncbi.nlm.nih.gov/21765152","citation_count":22,"is_preprint":false},{"pmid":"31438497","id":"PMC_31438497","title":"Microtubules: A Key to Understand and Correct Neuronal Defects in CDKL5 Deficiency Disorder?","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31438497","citation_count":21,"is_preprint":false},{"pmid":"25266480","id":"PMC_25266480","title":"Optimizing the molecular diagnosis of CDKL5 gene-related epileptic encephalopathy in boys.","date":"2014","source":"Epilepsia","url":"https://pubmed.ncbi.nlm.nih.gov/25266480","citation_count":21,"is_preprint":false},{"pmid":"33044867","id":"PMC_33044867","title":"Involvement of the CDKL5-SOX9 signaling axis in rhabdomyolysis-associated acute kidney injury.","date":"2020","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/33044867","citation_count":20,"is_preprint":false},{"pmid":"27840050","id":"PMC_27840050","title":"Subcellular distribution of cyclin-dependent kinase-like 5 (CDKL5) is regulated through phosphorylation by dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A).","date":"2016","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/27840050","citation_count":20,"is_preprint":false},{"pmid":"31232219","id":"PMC_31232219","title":"Aminoglycoside drugs induce efficient read-through of CDKL5 nonsense mutations, slightly restoring its kinase activity.","date":"2019","source":"RNA biology","url":"https://pubmed.ncbi.nlm.nih.gov/31232219","citation_count":20,"is_preprint":false},{"pmid":"26006105","id":"PMC_26006105","title":"Alteration of serum lipid profile, SRB1 loss, and impaired Nrf2 activation in CDKL5 disorder.","date":"2015","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26006105","citation_count":20,"is_preprint":false},{"pmid":"38081835","id":"PMC_38081835","title":"Epilepsy-linked kinase CDKL5 phosphorylates voltage-gated calcium channel Cav2.3, altering inactivation kinetics and neuronal excitability.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38081835","citation_count":19,"is_preprint":false},{"pmid":"25819767","id":"PMC_25819767","title":"Somatic mosaicism of a CDKL5 mutation identified by next-generation sequencing.","date":"2015","source":"Brain & development","url":"https://pubmed.ncbi.nlm.nih.gov/25819767","citation_count":19,"is_preprint":false},{"pmid":"36759195","id":"PMC_36759195","title":"Epilepsy-Related CDKL5 Deficiency Slows Synaptic Vesicle Endocytosis in Central Nerve Terminals.","date":"2023","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/36759195","citation_count":18,"is_preprint":false},{"pmid":"35445702","id":"PMC_35445702","title":"Touchscreen cognitive deficits, hyperexcitability and hyperactivity in males and females using two models of Cdkl5 deficiency.","date":"2022","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35445702","citation_count":18,"is_preprint":false},{"pmid":"30288694","id":"PMC_30288694","title":"Neuron-Type Specific Loss of CDKL5 Leads to Alterations in mTOR Signaling and Synaptic Markers.","date":"2018","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/30288694","citation_count":18,"is_preprint":false},{"pmid":"30561084","id":"PMC_30561084","title":"A framework for understanding quality of life domains in individuals with the CDKL5 deficiency disorder.","date":"2018","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/30561084","citation_count":18,"is_preprint":false},{"pmid":"36202289","id":"PMC_36202289","title":"Neuronal hyperexcitability and ion channel dysfunction in CDKL5-deficiency patient iPSC-derived cortical organoids.","date":"2022","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/36202289","citation_count":17,"is_preprint":false},{"pmid":"25905439","id":"PMC_25905439","title":"Critical Determinants of Substrate Recognition by Cyclin-Dependent Kinase-like 5 (CDKL5).","date":"2015","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25905439","citation_count":17,"is_preprint":false},{"pmid":"37011526","id":"PMC_37011526","title":"Efficacy, safety, and tolerability of soticlestat as adjunctive therapy for the treatment of seizures in patients with Dup15q syndrome or CDKL5 deficiency disorder in an open-label signal-finding phase II study (ARCADE).","date":"2023","source":"Epilepsy & behavior : E&B","url":"https://pubmed.ncbi.nlm.nih.gov/37011526","citation_count":17,"is_preprint":false},{"pmid":"34073043","id":"PMC_34073043","title":"Treatment with a GSK-3β/HDAC Dual Inhibitor Restores Neuronal Survival and Maturation in an In Vitro and In Vivo Model of CDKL5 Deficiency Disorder.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34073043","citation_count":17,"is_preprint":false},{"pmid":"16086395","id":"PMC_16086395","title":"Mutation analysis of the HDAC 1, 2, 8 and CDKL5 genes in Rett syndrome patients without mutations in MECP2.","date":"2005","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/16086395","citation_count":17,"is_preprint":false},{"pmid":"38326557","id":"PMC_38326557","title":"Cell type-specific expression, regulation and compensation of CDKL5 activity in mouse brain.","date":"2024","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/38326557","citation_count":17,"is_preprint":false},{"pmid":"35153983","id":"PMC_35153983","title":"Cortical Visual Impairment in CDKL5 Deficiency Disorder.","date":"2022","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/35153983","citation_count":16,"is_preprint":false},{"pmid":"28580010","id":"PMC_28580010","title":"Molecular and genetic insights into an infantile epileptic encephalopathy - CDKL5 disorder.","date":"2017","source":"Frontiers in biology","url":"https://pubmed.ncbi.nlm.nih.gov/28580010","citation_count":16,"is_preprint":false},{"pmid":"34028805","id":"PMC_34028805","title":"Cerebral visual impairment in CDKL5 deficiency disorder: vision as an outcome measure.","date":"2021","source":"Developmental medicine and child neurology","url":"https://pubmed.ncbi.nlm.nih.gov/34028805","citation_count":16,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50244,"output_tokens":6771,"usd":0.126148},"stage2":{"model":"claude-opus-4-6","input_tokens":10424,"output_tokens":4114,"usd":0.232455},"total_usd":0.358603,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2005,\n      \"finding\": \"CDKL5 is a functional kinase capable of autophosphorylation and phosphorylation of MeCP2 in vitro; CDKL5 and MeCP2 interact both in vivo and in vitro, placing them in a common molecular pathway.\",\n      \"method\": \"In vitro kinase assay, co-immunoprecipitation (in vivo and in vitro binding)\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinase assay with direct substrate phosphorylation; replicated by multiple labs\",\n      \"pmids\": [\"15917271\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Disease-causing mutations in CDKL5 alter catalytic activity (both impaired and increased) and impair phosphorylation of its TEY activation-loop motif; the C-terminal domain negatively regulates catalytic activity and is required for proper sub-nuclear localization; CDKL5 can self-associate and mediates autophosphorylation of its own TEY motif.\",\n      \"method\": \"In vitro kinase assay, site-directed mutagenesis, subcellular fractionation/localization studies\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinase assays combined with mutagenesis of disease-causing mutations and localization experiments\",\n      \"pmids\": [\"16935860\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CDKL5 kinase activity is required for its function; disease-associated mutations cause loss of kinase autophosphorylation activity; the C-terminal domain regulates CDKL5 expression and autophosphorylation and determines perinuclear localization when removed; MeCP2 binds CDKL5 but is not a direct substrate.\",\n      \"method\": \"In vitro kinase assay (autophosphorylation), immunoprecipitation, subcellular localization studies\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinase assays with multiple mutants; replicated findings on C-terminal regulation\",\n      \"pmids\": [\"16330482\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CDKL5 shuttles between cytoplasm and nucleus; the C-terminal tail localizes the protein to the cytoplasm via active nuclear export; disease-causing C-terminal truncations result in constitutive nuclear localization, suggesting gain-of-function in the nuclear compartment.\",\n      \"method\": \"Immunostaining, Western blotting, subcellular fractionation, nuclear export inhibition experiments\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct localization experiments with functional consequence; replicated across multiple CDKL5 studies\",\n      \"pmids\": [\"18701457\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CDKL5 binds the scaffolding protein PSD-95 in a palmitoylation-dependent manner, and this interaction promotes targeting of CDKL5 to excitatory synapses; pathogenic C-terminal truncations diminish CDKL5-PSD-95 binding and synaptic accumulation; loss of CDKL5 or disruption of the CDKL5-PSD-95 interaction inhibits dendritic spine formation and growth.\",\n      \"method\": \"Co-immunoprecipitation, RNAi knockdown, live imaging, spine morphology analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP with functional validation via RNAi and morphological readout\",\n      \"pmids\": [\"23671101\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Amphiphysin 1 (Amph1) is an endogenous cytoplasmic substrate of CDKL5; CDKL5 phosphorylates Amph1 at Ser-293; phosphorylation at this site reduces Amph1 affinity for endophilin, a protein involved in synaptic vesicle endocytosis; disease-causing missense mutations in the CDKL5 catalytic domain impair kinase activity toward Amph1.\",\n      \"method\": \"In vitro kinase assay, LC-MS/MS substrate identification, co-immunoprecipitation, mutagenesis\",\n      \"journal\": \"Archives of biochemistry and biophysics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinase assay with MS-identified phosphorylation site and functional consequence of phosphorylation\",\n      \"pmids\": [\"23651931\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"HDAC4 is a direct phosphorylation target of CDKL5; CDKL5-dependent phosphorylation promotes HDAC4 cytoplasmic retention; in Cdkl5 KO mice, hypophosphorylated HDAC4 translocates to the nucleus, binds chromatin and MEF2A transcription factor, leading to reduced histone 3 acetylation and altered neuronal gene expression.\",\n      \"method\": \"In vitro kinase assay, immunofluorescence, Cdkl5 KO mouse model, HDAC4 inhibitor rescue\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct substrate phosphorylation shown in vitro and validated in vivo with functional rescue\",\n      \"pmids\": [\"27466189\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Loss of CDKL5 in mice disrupts multiple signal transduction pathways including the AKT-mTOR cascade, as revealed by kinome profiling; Cdkl5 KO mice show autistic-like social deficits, motor impairment, and fear memory impairment.\",\n      \"method\": \"Cdkl5 KO mouse model, kinome profiling, behavioral assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse with defined behavioral phenotype + kinome profiling establishing pathway disruption\",\n      \"pmids\": [\"23236174\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Loss of CDKL5 impairs hippocampal neurogenesis: increases proliferation of neural precursors, increases apoptosis of postmitotic granule neuron precursors, reduces total granule cell number, and causes severe dendritic hypotrophy; these defects are associated with impaired AKT/GSK-3β signaling.\",\n      \"method\": \"Cdkl5 KO mouse model, immunostaining, Western blotting, hippocampus-dependent memory assays\",\n      \"journal\": \"Neurobiology of disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse with multiple cellular phenotypes linked to specific signaling pathway\",\n      \"pmids\": [\"24952363\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Using chemical genetics, CDKL5 was found to phosphorylate three microtubule-associated proteins: MAP1S, EB2, and ARHGEF2 at defined sites; substrate phosphorylations are reduced in CDKL5 KO mouse neurons; CDKL5 regulates dendritic microtubule dynamics via phosphorylation of MAP1S, which promotes MAP1S dissociation from microtubules; anterograde cargo trafficking is compromised in CDKL5 KO dendrites.\",\n      \"method\": \"Chemical genetics (analog-sensitive kinase), phosphoproteomics, shRNA rescue, live imaging of EB3-GFP microtubule dynamics in KO neurons\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — chemical genetic substrate identification with in vivo validation and functional microtubule dynamics assay\",\n      \"pmids\": [\"30266824\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Quantitative phosphoproteomic screening identified MAP1S (pSer900), CEP131 (pSer35), and DLG5 as cellular CDKL5 substrates; the consensus phosphorylation motif for CDKL5 is RPXSA; pathogenic CDKL5 mutations cause major reduction in CDKL5 activity both in vitro and in cells.\",\n      \"method\": \"Quantitative phosphoproteomics, phospho-specific antibodies, in vitro kinase assays with disease mutants\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — phosphoproteomic screen validated with phospho-specific antibodies and in vitro kinase assays\",\n      \"pmids\": [\"30266825\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CDKL5 controls postsynaptic localization of GluN2B-containing NMDA receptors and SAP102 in hippocampal CA1; Cdkl5 KO mice show increased NMDA/AMPA ratio and prolonged NMDA-EPSC decay; GluN2B and SAP102 are overaccumulated in the postsynaptic density of Cdkl5 KO mice; GluN2B-selective antagonist ifenprodil abrogates NMDA-induced hyperexcitability.\",\n      \"method\": \"Cdkl5 KO mouse, electrophysiology (patch-clamp), subcellular fractionation, immunoelectron microscopy\",\n      \"journal\": \"Neurobiology of disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse with electrophysiology, fractionation, and immunoEM; multiple orthogonal methods\",\n      \"pmids\": [\"28688852\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Loss of CDKL5 specifically in forebrain glutamatergic neurons impairs hippocampal-dependent memory; CDKL5-deficient pyramidal neurons show decreased dendritic complexity, increased mEPSC and mIPSC frequency, and hyperexcitability in dendritic domains constrained by elevated inhibition.\",\n      \"method\": \"Conditional KO mouse (glutamatergic neuron-specific), behavioral assays, patch-clamp electrophysiology, voltage-sensitive dye imaging\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-type specific KO with defined behavioral and circuit phenotypes using multiple methods\",\n      \"pmids\": [\"28674172\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CDKL5 interacts with shootin1, a brain-specific determinant of axon formation; CDKL5 and shootin1 co-localize at the distal tip of outgrowing axons; CDKL5 overexpression causes supernumerary axons while silencing disrupts neuronal polarization; shootin1 phosphorylation is reduced in CDKL5-silenced neurons; the two proteins act in a common pathway for axon specification.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, live imaging, RNAi silencing, overexpression in primary hippocampal neurons\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — co-IP validated interaction with functional neuronal polarization phenotype; single lab\",\n      \"pmids\": [\"26849555\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CDKL5 interacts with IQGAP1; loss of CDKL5 impairs cell migration and IQGAP1 localization at the leading edge; CDKL5 is required for IQGAP1 to form a functional complex with Rac1 and CLIP170 (microtubule plus-end tracking protein), thereby regulating microtubule dynamics.\",\n      \"method\": \"Co-immunoprecipitation, cell migration assay, immunofluorescence localization, rescue with pregnenolone\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — co-IP with functional migration and microtubule dynamics readout; single lab\",\n      \"pmids\": [\"28641386\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Neuronal depolarization induces rapid increase in CDKL5 levels via extrasomatic synthesis; in mature neurons, NMDA receptor stimulation induces protein phosphatase 1-dependent dephosphorylation of CDKL5 that is required for its proteasome-dependent degradation, providing activity-dependent control of CDKL5 levels.\",\n      \"method\": \"Primary neuron cultures, pharmacological inhibitors, metabolic labeling, proteasome inhibition\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple pharmacological approaches in primary neurons; single lab\",\n      \"pmids\": [\"25555910\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"DYRK1A binds to and phosphorylates CDKL5 at Ser-308 (near the nuclear localization signal); phosphorylation at Ser-308 promotes cytosolic localization of CDKL5; the phosphomimetic S308D mutation shifts CDKL5 to cytoplasm while S308A remains nuclear.\",\n      \"method\": \"Co-immunoprecipitation, site-directed mutagenesis, subcellular localization experiments in Neuro2a cells\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — co-IP with mutagenesis and localization readout; single lab\",\n      \"pmids\": [\"27840050\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CDKL5 (Cdkl5) is a MeCP2-repressed target gene; increased MeCP2 levels repress Cdkl5 expression in rat brain; Cdkl5 is regulated by DNA methylation, as DNMT inhibitors or MeCP2 knockdown induce its expression; cocaine increases Cdkl5 gene methylation and MeCP2 binding to the Cdkl5 locus in striatum.\",\n      \"method\": \"siRNA knockdown, MeCP2 overexpression, DNMT inhibitor treatment, ChIP, in vivo cocaine model\",\n      \"journal\": \"Neurobiology of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal approaches showing MeCP2-dependent transcriptional regulation; single lab\",\n      \"pmids\": [\"20211261\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Selective loss of CDKL5 in GABAergic neurons leads to autistic-like phenotypes accompanied by excessive glutamatergic transmission and increased postsynaptic NMDA receptor levels; acute low-dose NMDAR inhibition ameliorates autistic-like behaviors in GABAergic CDKL5 KO mice and in a CDD-associated R59X knockin mouse.\",\n      \"method\": \"GABAergic-neuron-specific conditional KO mouse, R59X knockin mouse, behavioral assays, electrophysiology, receptor level measurements\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-type specific KO with behavioral, electrophysiological and molecular phenotyping; replicated in two mouse models\",\n      \"pmids\": [\"31201320\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CDKL5 is recruited to sites of DNA damage in actively transcribed nuclear regions; a phosphoproteomic screen identified Elongin A (ELOA) as a nuclear CDKL5 substrate phosphorylated at a CDKL5 consensus motif; recruitment of CDKL5 and ELOA requires active transcription and poly(ADP-ribose) (PAR) synthesis; CDKL5 can bind PAR; CDKL5 kinase activity is essential for transcriptional silencing induced by DNA double-strand breaks.\",\n      \"method\": \"Live-cell imaging of DNA damage recruitment, quantitative phosphoproteomics, PAR binding assay, kinase-inactive mutant analysis\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — phosphoproteomic substrate identification with functional validation using kinase-inactive mutants and direct PAR binding\",\n      \"pmids\": [\"34605059\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SMAD3 is a direct phosphorylation target of CDKL5; CDKL5-dependent phosphorylation promotes SMAD3 protein stability; restoration of SMAD3 signaling via TGF-β1 normalizes defective neuronal survival and maturation in Cdkl5 KO neurons and prevents NMDA-induced hippocampal cell death in vivo.\",\n      \"method\": \"In vitro kinase assay, Cdkl5 KO mouse model, TGF-β1 in vivo treatment, immunostaining\",\n      \"journal\": \"Brain pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro kinase assay plus KO mouse rescue experiment; single lab\",\n      \"pmids\": [\"30793413\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CDKL5 phosphorylates SOX9, suppressing its pro-survival transcriptional activity in renal tubular epithelial cells; Cdkl5 genetic or pharmacological inhibition mitigates nephrotoxic and ischemia-associated acute kidney injury in mouse models.\",\n      \"method\": \"Kinome RNAi screen, kinase assay (activation-specific antibodies), RTEC-specific Cdkl5 KO mouse, small molecule inhibitor (AST-487)\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — kinase assay validation, cell-type specific KO, and pharmacological rescue; multiple orthogonal approaches\",\n      \"pmids\": [\"32317630\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CDKL5 overexpression arrests the cell cycle at G0/G1 and induces cellular differentiation in neuroblastoma cells; CDKL5 expression is directly repressed by MYCN transcription factor, which binds the CDKL5 promoter.\",\n      \"method\": \"Cell cycle analysis (flow cytometry), differentiation assays, ChIP, promoter reporter assays, MYCN overexpression/knockdown\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple complementary approaches in a single study; functional cell cycle phenotype with defined transcriptional mechanism\",\n      \"pmids\": [\"22921766\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CDKL5 phosphorylates the voltage-gated Ca2+ channel Cav2.3 (encoded by CACNA1E) as a physiological substrate in mice and humans; loss of Cav2.3 phosphorylation leads to channel gain-of-function via slower inactivation and enhanced cholinergic stimulation, resulting in increased neuronal excitability; Cav2.3 phosphomutant mice recapitulate aspects of CDD.\",\n      \"method\": \"SILAC-based phosphoproteomic screen, recombinant channel electrophysiology, Cav2.3 phosphomutant mouse model, interdisciplinary phenotyping\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — phosphoproteomic substrate identification combined with reconstituted channel electrophysiology and in vivo knockin mouse\",\n      \"pmids\": [\"38081835\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CDKL5 kinase activity is required for efficient synaptic vesicle (SV) endocytosis in central nerve terminals; kinase-inactive CDKL5 mutations fail to restore SV endocytosis in Cdkl5 KO rat neurons; the isolated CDKL5 kinase domain is sufficient to rescue SV endocytosis; amphiphysin 1 phosphorylation is not required for this presynaptic role.\",\n      \"method\": \"Cdkl5 KO rat primary hippocampal neurons, genetically encoded SV reporter, kinase-inactive mutant rescue, isolated kinase domain rescue\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinase requirement established with kinase-inactive mutants and domain rescue in KO neurons\",\n      \"pmids\": [\"36759195\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CDKL5 substrate recognition requires an arginyl residue at the P-3 position and a prolyl residue at P-2 relative to the phospho-acceptor serine; the consensus motif is RPXSX; the CLAP domain structure of amphiphysin 1 is also required for efficient phosphorylation.\",\n      \"method\": \"In vitro kinase assay with point-mutant and deletion-mutant substrates (Amph1 and Amph2)\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic in vitro mutagenesis defining substrate consensus motif\",\n      \"pmids\": [\"25905439\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Postdevelopmental loss of CDKL5 disrupts hippocampal circuit communication, dendritic spine morphology, and multiple behavioral domains; restoration of Cdkl5 expression after early development ameliorates CDD-related behavioral impairments and aberrant NMDA receptor signaling, demonstrating reversibility of CDKL5 deficiency phenotypes.\",\n      \"method\": \"Conditional temporal Cdkl5 KO and rescue mouse models, behavioral assays, electrophysiology, spine morphology analysis\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — temporal conditional KO and rescue in mice with behavioral and electrophysiological readouts; multiple orthogonal methods\",\n      \"pmids\": [\"34651584\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CDKL5 and EB2 phospho-Ser222 (a CDKL5 substrate) are expressed in excitatory and inhibitory neurons but not astrocytes; approximately 15-20% of EB2 pS222 remains in Cdkl5 KO brains, attributable to a compensating kinase activity; CDKL2 and ICK can phosphorylate EB2 S222; dual Cdkl5/Cdkl2 KO mice demonstrate that CDKL2 phosphorylates CDKL5 substrates in vivo.\",\n      \"method\": \"Conditional Cdkl5 KO mice (excitatory, inhibitory, astrocyte-specific), phospho-specific antibody for EB2 pS222, kinase screen in HEK293T cells, dual KO mouse\",\n      \"journal\": \"Molecular psychiatry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-type specific KO combined with in vivo phospho-antibody readout and genetic validation via dual KO\",\n      \"pmids\": [\"38326557\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CDKL5 is a brain-enriched serine/threonine kinase that phosphorylates multiple substrates—including MeCP2, HDAC4, SMAD3, MAP1S, EB2, ARHGEF2, CEP131, DLG5, amphiphysin 1, Cav2.3, and Elongin A—using a consensus RPX(S/T) motif; its catalytic activity is regulated by autophosphorylation of a TEY activation loop, phosphorylation by DYRK1A at Ser-308 (controlling nuclear/cytoplasmic distribution), activity-dependent dephosphorylation by PP1 and proteasomal degradation; through these substrates CDKL5 controls dendritic microtubule dynamics, synaptic vesicle endocytosis, postsynaptic NMDA and AMPA receptor localization, dendritic spine morphogenesis, neuronal polarization, transcription-coupled DNA damage responses, and neuronal survival, with loss of CDKL5 function disrupting AKT/GSK-3β, mTOR, and HDAC4/MEF2A signaling pathways to cause the epileptic encephalopathy and neurodevelopmental deficits characteristic of CDKL5 deficiency disorder.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CDKL5 is a brain-enriched serine/threonine kinase that controls dendritic morphogenesis, synaptic function, neuronal excitability, and survival by phosphorylating diverse substrates at a consensus RPX(S/T) motif. Its catalytic activity, regulated by autophosphorylation of a TEY activation-loop motif and by DYRK1A-mediated phosphorylation at Ser-308 controlling nuclear–cytoplasmic shuttling, targets microtubule regulators (MAP1S, EB2, ARHGEF2), synaptic proteins (amphiphysin 1, PSD-95-associated complexes, Cav2.3), transcriptional regulators (HDAC4, SMAD3, Elongin A), and centrosomal/polarity factors (CEP131, DLG5), thereby governing dendritic microtubule dynamics, synaptic vesicle endocytosis, NMDA receptor localization, and transcription-coupled DNA damage responses [PMID:30266824, PMID:30266825, PMID:23651931, PMID:27466189, PMID:34605059, PMID:38081835, PMID:36759195]. Loss-of-function mutations cause CDKL5 deficiency disorder, an epileptic encephalopathy with neurodevelopmental deficits characterized by disrupted AKT/GSK-3β and mTOR signaling, NMDA receptor overaccumulation, and dendritic hypotrophy, phenotypes that are reversible upon postnatal gene restoration in mice [PMID:23236174, PMID:24952363, PMID:28688852, PMID:34651584]. CDKL2 and ICK provide partially compensatory kinase activity toward CDKL5 substrates such as EB2 in vivo [PMID:38326557].\",\n  \"teleology\": [\n    {\n      \"year\": 2005,\n      \"claim\": \"Establishing that CDKL5 is a functional kinase that autophosphorylates and interacts with MeCP2 placed CDKL5 into an active signaling pathway rather than being merely a disease-associated gene of unknown function.\",\n      \"evidence\": \"In vitro kinase assay and co-immunoprecipitation in mammalian cells\",\n      \"pmids\": [\"15917271\", \"16330482\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether MeCP2 is a direct physiological substrate remained disputed between the two 2005 studies\",\n        \"Endogenous substrates in neurons were unknown\",\n        \"Upstream regulators of CDKL5 kinase activity were undefined\"\n      ]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Demonstrating that disease-causing mutations alter TEY activation-loop phosphorylation and that the C-terminal domain negatively regulates catalytic activity and nuclear localization established the first structure–function framework for CDKL5.\",\n      \"evidence\": \"Site-directed mutagenesis of patient mutations with in vitro kinase assays and subcellular fractionation\",\n      \"pmids\": [\"16935860\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Crystal structure of the kinase domain was unavailable\",\n        \"The mechanism by which the C-terminal tail inhibits catalysis was undefined\",\n        \"Whether TEY phosphorylation is purely autophosphorylation or also mediated by upstream kinases was unresolved\"\n      ]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Showing that CDKL5 actively shuttles between nucleus and cytoplasm, with disease-causing C-terminal truncations causing constitutive nuclear accumulation, revealed that mislocalization is a pathogenic mechanism.\",\n      \"evidence\": \"Immunostaining, subcellular fractionation, and nuclear export inhibition in cell lines\",\n      \"pmids\": [\"18701457\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"The nuclear export signal sequence was not precisely mapped\",\n        \"Functional consequences of nuclear-restricted CDKL5 in neurons were untested\"\n      ]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Cdkl5 knockout mice displaying autistic-like behaviors and disrupted AKT-mTOR signaling established the first in vivo disease model and identified downstream pathway perturbations, while parallel work showed CDKL5 can arrest cell cycle and is transcriptionally repressed by MYCN.\",\n      \"evidence\": \"Cdkl5 KO mouse behavioral and kinome profiling; cell cycle analysis and ChIP in neuroblastoma cells\",\n      \"pmids\": [\"23236174\", \"22921766\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether AKT-mTOR disruption is a direct or indirect consequence of CDKL5 loss was unknown\",\n        \"Cell-type contributions to behavioral phenotypes were unresolved\"\n      ]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identification of amphiphysin 1 as a direct substrate (pSer-293) linking CDKL5 to synaptic vesicle endocytosis, and of the PSD-95 interaction linking CDKL5 to excitatory synapse targeting and dendritic spine formation, provided the first mechanistic connections between CDKL5 kinase activity and synaptic biology.\",\n      \"evidence\": \"LC-MS/MS substrate mapping, co-IP of CDKL5–PSD-95, RNAi-mediated loss-of-function with spine morphology readout\",\n      \"pmids\": [\"23651931\", \"23671101\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether amphiphysin 1 phosphorylation fully explains presynaptic defects was untested\",\n        \"The palmitoylation site on CDKL5 required for PSD-95 binding was not identified\"\n      ]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Systematic mutagenesis defined the CDKL5 substrate consensus motif as RPX(S/T), and activity-dependent regulation of CDKL5 protein levels via PP1 dephosphorylation and proteasomal degradation was discovered, linking synaptic activity to kinase abundance.\",\n      \"evidence\": \"In vitro kinase assays with point-mutant substrates; pharmacological dissection of CDKL5 turnover in primary neurons\",\n      \"pmids\": [\"25905439\", \"25555910\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"The specific phosphosites on CDKL5 targeted by PP1 for degradation were not mapped\",\n        \"In vivo relevance of activity-dependent CDKL5 degradation was not tested\"\n      ]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identification of HDAC4 and shootin1 as CDKL5 targets/interactors expanded the functional repertoire to include epigenetic regulation (HDAC4 cytoplasmic retention controlling MEF2A-dependent transcription) and neuronal polarization (axon specification via shootin1), while DYRK1A-mediated Ser-308 phosphorylation was found to control CDKL5 nuclear–cytoplasmic distribution.\",\n      \"evidence\": \"In vitro kinase assays, Cdkl5 KO mouse with HDAC4 inhibitor rescue, yeast two-hybrid and co-IP for shootin1, mutagenesis of Ser-308\",\n      \"pmids\": [\"27466189\", \"26849555\", \"27840050\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"The specific HDAC4 phosphosite(s) were not fully mapped\",\n        \"Shootin1 interaction was from a single lab and awaits independent confirmation\",\n        \"Whether DYRK1A regulation of CDKL5 localization occurs in vivo in neurons was untested\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Cell-type-specific knockout studies demonstrated that CDKL5 loss in forebrain glutamatergic neurons causes hippocampal memory deficits, dendritic hypotrophy, and altered excitability, while molecular analysis revealed overaccumulation of GluN2B-NMDA receptors at postsynaptic densities as a key pathogenic mechanism.\",\n      \"evidence\": \"Glutamatergic-neuron conditional KO mice, electrophysiology, immunoelectron microscopy, GluN2B-selective antagonist rescue\",\n      \"pmids\": [\"28674172\", \"28688852\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether CDKL5 directly phosphorylates NMDA receptor subunits or acts indirectly was unknown\",\n        \"Contribution of GABAergic neuron CDKL5 loss was untested at this point\"\n      ]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Chemical-genetic and quantitative phosphoproteomic screens converged on MAP1S, EB2, ARHGEF2, CEP131, and DLG5 as bona fide CDKL5 substrates, establishing that CDKL5 controls dendritic microtubule dynamics through MAP1S phosphorylation-dependent dissociation from microtubules.\",\n      \"evidence\": \"Analog-sensitive kinase allele, SILAC phosphoproteomics, phospho-specific antibodies, live EB3-GFP imaging in KO neurons\",\n      \"pmids\": [\"30266824\", \"30266825\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Functional roles of CEP131 and DLG5 phosphorylation were not characterized\",\n        \"Whether microtubule dynamics defects underlie spine morphology changes was not directly tested\"\n      ]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"GABAergic-neuron-specific CDKL5 loss was shown to cause autistic-like behaviors with excessive NMDA signaling, rescuable by low-dose NMDAR antagonism, while SMAD3 was identified as a CDKL5 substrate whose phosphorylation promotes neuronal survival via TGF-β signaling.\",\n      \"evidence\": \"GABAergic conditional KO and R59X knockin mice with NMDAR antagonist rescue; in vitro kinase assay for SMAD3 with TGF-β1 in vivo rescue in KO\",\n      \"pmids\": [\"31201320\", \"30793413\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"The presynaptic versus postsynaptic locus of NMDAR dysregulation in GABAergic KO was unclear\",\n        \"SMAD3 as a substrate was from a single lab and the specific phosphosite was not fully characterized\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"CDKL5 was found to be recruited to transcription-coupled DNA damage sites via PAR binding, where it phosphorylates Elongin A to silence transcription at breaks, revealing an unexpected nuclear function beyond synaptic signaling; separately, temporal rescue experiments demonstrated that CDD phenotypes are reversible upon postnatal CDKL5 restoration.\",\n      \"evidence\": \"Live-cell DNA damage imaging, phosphoproteomics identifying Elongin A, PAR-binding assay; conditional temporal KO/rescue mice with behavioral and electrophysiological readouts\",\n      \"pmids\": [\"34605059\", \"34651584\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether transcription-coupled DNA damage repair contributes to CDD neuropathology is unknown\",\n        \"The degree of phenotypic rescue achievable in adult animals was not fully explored\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Cav2.3 was identified as a physiological CDKL5 substrate whose phosphorylation accelerates channel inactivation; loss of this phosphorylation causes channel gain-of-function and neuronal hyperexcitability, directly connecting CDKL5 loss to ion channel dysfunction, while CDKL5 kinase activity was separately shown to be required for efficient synaptic vesicle endocytosis independent of amphiphysin 1 phosphorylation.\",\n      \"evidence\": \"SILAC phosphoproteomics, recombinant channel electrophysiology, Cav2.3 phosphomutant knockin mouse; Cdkl5 KO rat neurons with SV reporter and kinase-dead rescue\",\n      \"pmids\": [\"38081835\", \"36759195\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"The specific CDKL5 substrate mediating synaptic vesicle endocytosis (if not amphiphysin 1) is unknown\",\n        \"Whether Cav2.3 phosphorylation loss accounts for seizure susceptibility in CDD patients is untested\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Dual knockout experiments revealed that CDKL2 provides compensatory phosphorylation of CDKL5 substrates (notably EB2 at Ser-222) in vivo, establishing kinase redundancy that must be considered when interpreting single-KO phenotypes.\",\n      \"evidence\": \"Cell-type specific Cdkl5 KO with phospho-EB2 antibody; HEK293T kinase screen; Cdkl5/Cdkl2 dual KO mouse\",\n      \"pmids\": [\"38326557\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"The full set of substrates shared between CDKL5 and CDKL2 is undefined\",\n        \"Whether CDKL2 compensation is neuroprotective or masks disease severity in CDD is unknown\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of CDKL5 substrate recognition, the identity of the presynaptic substrate(s) required for synaptic vesicle endocytosis, whether transcription-coupled DNA damage repair contributes to CDD neuropathology, and the extent to which CDKL2/ICK compensation modulates disease severity.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No crystal or cryo-EM structure of full-length CDKL5 with substrate or regulatory domains\",\n        \"Presynaptic CDKL5 substrate for SV endocytosis remains unidentified\",\n        \"Contribution of nuclear DNA damage response function to neurological phenotypes is untested\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 5, 6, 9, 10, 19, 20, 21, 23, 25]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 5, 6, 10, 23, 25]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 3, 19]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [3, 5, 16]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [7, 8, 20]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [4, 9, 11, 12, 18, 23, 24]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [19]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [8, 13]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"MECP2\",\n      \"DLG4\",\n      \"AMPH\",\n      \"HDAC4\",\n      \"MAP1S\",\n      \"MAPRE2\",\n      \"DYRK1A\",\n      \"IQGAP1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}